Biogen (BIIB) and Eisai's (ESALF) (ESAIY) announce that U.S. FDA agreed to review their subcutaneous form of Alzheimer's ...
Right before the turn of the new year, the Tennessee Department of Correction (TDOC) announced it had created a new protocol ...
TipRanks on MSN13h
FDA accepts Eisai/Biogen’s BLA for LEQEMBI in early AD treatmentEisai (ESAIY) and Biogen (BIIB) announced that the FDA has accepted Eisai’s Biologics License Application, BLA, for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback